Literature DB >> 22526387

Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study.

Koichiro Yoshida1, Atsuyuki Kurashima, Katsuhiko Kamei, Masaru Oritsu, Tsunehiro Ando, Toshinori Yamamoto, Yoshihito Niki.   

Abstract

In the respiratory field, chronic pulmonary aspergillosis, such as chronic necrotizing pulmonary aspergillosis (CNPA) or aspergilloma, is important. We examined the efficacy and safety of short- and long-term itraconazole (ITCZ) administration, involving a switch from injection to an oral preparation, in patients with CNPA. In all hospitals participating in this study, the protocol was approved by the ethics review board. This study started after UMIN registration (UMIN000001727). Subjects enrolled in this study were patients who were clinically or definitively diagnosed with CNPA in the respiratory field, according to the diagnostic criteria of the Japanese "Guidelines for management of deep-seated mycosis 2007," in 16 hospitals that participated in this study between May 2008 and March 2011. Treatment was started with ITCZ injection. Subsequently, the agent was switched to an oral preparation. Efficacy was evaluated with major items (clinical symptoms, fever, imaging findings) and minor items (nutritional status, inflammatory markers). Twenty-nine patients were enrolled; safety was evaluated in 24 and efficacy in 23. Of the 23 patients, 10 (43.5 %) responded. With respect to the administration period, the response rates in 8 patients treated for a short period and 15 treated for a long period were 25.0 % and 53.3 %, respectively. Trough blood concentration of ITCZ reached a level at which ITCZ may be effective for aspergillosis at 3 days after the start of ITCZ injection therapy. After changing to high-dose capsules, its level was also maintained. Adverse events such as liver dysfunction and heart failure were observed in 9 of the 24 patients. Furthermore, 6 patients died. However, there was no relationship between these events and ITCZ. Step-down therapy from ITCZ injection to oral administration may be a useful treatment option in CNPA patients requiring long-term treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526387     DOI: 10.1007/s10156-012-0414-7

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  6 in total

1.  Chronic necrotizing pulmonary aspergillosis in an immunocompetent patient: report of a rare case.

Authors:  E Jin; L M Wang; Q Y Li; X Feng; S L Ma
Journal:  Infection       Date:  2014-01-01       Impact factor: 3.553

2.  Trough concentration of itraconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.

Authors:  Jingru Zhang; Yiwei Liu; Xiaolu Nie; Yuncui Yu; Jian Gu; Libo Zhao
Journal:  Infect Drug Resist       Date:  2018-08-22       Impact factor: 4.003

Review 3.  Invasive Aspergillus outbreak in inhalation injury: a case presentation and literature review.

Authors:  Shengli Liu; Zonghang Li; Jiansheng Zheng; Ning He
Journal:  BMC Infect Dis       Date:  2022-04-18       Impact factor: 3.667

Review 4.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

5.  Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.

Authors:  Felix Bongomin; Chris Harris; Gemma Hayes; Chris Kosmidis; David W Denning
Journal:  PLoS One       Date:  2018-04-10       Impact factor: 3.240

6.  Underlying Conditions and Clinical Spectrum of Chronic Pulmonary Aspergillosis (CPA): An Experience from a Tertiary Care Hospital in Karachi, Pakistan.

Authors:  Nousheen Iqbal; Muhammad Irfan; Ammar Mushtaq; Kauser Jabeen
Journal:  J Fungi (Basel)       Date:  2020-03-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.